Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected to Announce Earnings of -$0.16 Per Share

Equities research analysts expect that Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating) will announce ($0.16) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences posted earnings of ($0.12) per share during the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Anavex Life Sciences will report full year earnings of ($0.91) per share for the current financial year, with EPS estimates ranging from ($1.32) to ($0.67). For the next year, analysts anticipate that the firm will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.62) to $0.17. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Anavex Life Sciences.

Anavex Life Sciences (NASDAQ:AVXLGet Rating) last posted its earnings results on Wednesday, February 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. During the same quarter last year, the company posted ($0.12) EPS.

A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, April 13th. HC Wainwright reissued a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research report on Wednesday, March 16th. Finally, StockNews.com initiated coverage on shares of Anavex Life Sciences in a research report on Thursday, March 31st. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $33.17.

Institutional investors and hedge funds have recently bought and sold shares of the company. Liberty One Investment Management LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth approximately $184,000. Principal Financial Group Inc. grew its position in shares of Anavex Life Sciences by 4.8% during the third quarter. Principal Financial Group Inc. now owns 27,198 shares of the biotechnology company’s stock worth $488,000 after buying an additional 1,234 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Anavex Life Sciences during the third quarter worth approximately $64,000. Cetera Advisor Networks LLC acquired a new stake in shares of Anavex Life Sciences during the third quarter worth approximately $558,000. Finally, GSA Capital Partners LLP grew its position in shares of Anavex Life Sciences by 78.2% during the third quarter. GSA Capital Partners LLP now owns 30,301 shares of the biotechnology company’s stock worth $544,000 after buying an additional 13,298 shares in the last quarter. Institutional investors own 28.61% of the company’s stock.

AVXL opened at $10.44 on Thursday. The firm has a 50 day moving average price of $11.58 and a 200 day moving average price of $15.27. The company has a market cap of $803.01 million, a PE ratio of -18.98 and a beta of 0.73. Anavex Life Sciences has a 1 year low of $9.28 and a 1 year high of $31.50.

Anavex Life Sciences Company Profile (Get Rating)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.

Further Reading

Get a free copy of the Zacks research report on Anavex Life Sciences (AVXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.